Table 1 Clinical, demographic, and MSCT data of the entire MSCT cohort (n = 67)

Women

[n,%]

35, 52%

Median age (range)

[years]

61 (21 – 87)

Median BMI (range)

[kg/m²]

24 (17 – 53)

Median time ESRD (range)

[months]

49 (2 – 364)

Previous renal transplant

[n,%]

21, 31%

Current smoking

[n,%]

10, 15%

History of CVD

[n,%]

25, 37%

History of CAD

[n,%]

22, 33%

Diabetes

[n,%]

15, 22%

History of PAD

[n,%]

9, 13%

History of MI

[n,%]

9, 13%

History of PTex

[n,%]

9, 13%

Median CAC Agatston (range) (n = 65)

279 (0 – 3736)

Median Mass CAC (range) (n = 65)

51 (0 – 643)

Median Volume CAC (range) (n = 65)

261 (0 – 3267)

Median AVC Agatston (range)

0 (0 – 1596)

Median Mass AVC (range)

0 (0 – 284)

Median Volume AVC (range)

0 (0 – 1316)

CAC Agatston score >100

[n,%]

44, 66%

Any AVC

[n,%]

27, 40%

Usage of Phosphate binders

[n,%]

61, 92%

Calcium-based

[n,%]

51, 77%

Aluminum-based

[n,%]

14, 22%

Calcimimetics

[n,%]

16, 25%